Details

Autor(en) / Beteiligte

• Lee, Rex H.
• Truong, Angeline
• Wu, Xin
• Kang, Hyunseok
• Algazi, Alain P.
• El‐Sayed, Ivan H.
• George, Jonathan R.
• Heaton, Chase M.
• Ryan, William R.
• Ha, Patrick K.
• Wai, Katherine C.

Titel

The neutrophil‐to‐lymphocyte ratio in salivary gland cancers treated with pembrolizumab

Ist Teil von

• Head & neck, 2024-01, Vol.46 (1), p.129-137

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Wiley-Blackwell Full Collection

Beschreibungen/Notizen

• Background A minority of patients with recurrent/metastatic (R/M) salivary gland cancers (SGCs) benefit from immune checkpoint inhibitors (ICIs), necessitating reliable biomarkers for ICI response prediction. Methods Retrospective observational study of R/M SGC patients treated with pembrolizumab between 2016 and 2022, with a primary outcome of 6‐month progression‐free survival (PFS) and secondary outcome of 2‐year overall survival (OS). Univariate and multivariable Cox proportional hazards models were employed. Results Twenty R/M SGC patients were included. After adjustment, NLR as a continuous variable was independently associated with 6‐month PFS (HR 1.30, 95% CI 1.10–1.54, p = 0.002) and 2‐year OS (HR 1.33, 95% CI 1.07–1.66, p = 0.010). Similarly, NLR ≥ 5 was associated with higher hazards of progression at 6 months (HR 12.85, 95% CI 2.17–76.16, p = 0.005) and death at 2 years (HR 11.25, 95% CI 1.67–75.77, p = 0.013). Conclusions Higher pretreatment NLR was independently associated with inferior 6‐month PFS and 2‐year OS in pembrolizumab‐treated R/M SGC patients.